Sanigen (188260.KQ) Stock
Sanigen

Company profile
Sanigen reported revenue of 15.35 billion KRW for fiscal year 2025, and a net loss of 5.82 billion KRW. That is a net profit margin of -37.9% for fiscal year 2025. Our analysis of its filings shows revenue shrinking from 22.27 billion KRW in fiscal year 2023 to 15.35 billion KRW in fiscal year 2025, 17.0% a year on average.
What stands out
- It reported a net loss in each of its last 5 fiscal years (2021 to 2025).
- Revenue fell 36.1% in fiscal year 2025, from 24.01 billion KRW in fiscal year 2024, after a rise of 7.8% the year before.
- Its net profit margin over the last four reported quarters was -27.4%, against a median of -2.5% for 6 listed companies of similar size in its industry.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Sanigen
Sanigen Co. Ltd, a food sanitation and safety specialist, develops and services solutions for safe food manufacturing, distribution, and sales in Korea and internationally. The company offers PCR detection and nucleic acid extraction kits; bag, diluent, beam template, macroswab, and squeeze products; pathogen detection NGS panel kits; and hand sanitizers, vomit clean up kits, and pure systems. It also provides Microbial, physicochemical analysis, and food sanitation/lab services. Sanigen Co. Ltd was founded in 2005 and is headquartered in Anyang-si, South Korea.
Largest shareholders
- Jung-Woong Park15.78 %15.78%
Share of the company, as of September 25, 2026
Leadership
- Park Jeong Woong — Chairman & CEO, 56
- Gyeong-il Jeon — Sales Director & Director, 48
- Jong-wook Bang — Executive Director, 52
- SungJin Sim — Head of Management Support Division & Executive Director, 43
- SiBeom Song — Head of Production Division & Executive Director, 50
How much revenue does Sanigen make?
Sanigen reported 15.35 billion KRW in revenue for fiscal year 2025, down 36.1% from 24.01 billion KRW in fiscal year 2024.
What companies are similar to Sanigen?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Myungmoon Pharm co.,Ltd (017180.KS), Bcworld Pharm. Co., Ltd. (200780.KQ), Korea Arlico Pharm Co.,Ltd. (260660.KQ), Aprogen Biologics Inc. (003060.KS).
Has Sanigen made a profit in recent years?
Net income by fiscal year: FY2021, a loss of 4.28 billion KRW; FY2022, a loss of 4.06 billion KRW; FY2023, a loss of 8.78 billion KRW; FY2024, a loss of 5.07 billion KRW; FY2025, a loss of 5.82 billion KRW. It reported a net loss in each of these 5 years.
How has Sanigen's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 25.22 billion KRW; FY2022, 26.76 billion KRW; FY2023, 22.27 billion KRW; FY2024, 24.01 billion KRW; FY2025, 15.35 billion KRW.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Sanigen (188260.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/188260.KQ